Sugi Predict

Sugi Predict / Compounds / SCHEMBL4086089

SCHEMBL4086089

SCHEMBL4086089

CNC(=O)Nc1cc(-c2cccc(NC(=O)c3ccc(Oc4ccccc4)cc3)c2C)nn2ccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.52
▸ SYK P43405 3/20 0.42
▸ KDR P35968 2/20 0.42
▸ GCK P35557 1/20 0.41
▸ TP53 P04637 2/20 0.41
▸ GRM5 P41594 1/20 0.40
▸ MAPT P10636 3/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ AURKB Q96GD4 1/20 0.39
▸ SERPINE1 P05121 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095844 0.90 BTK (0.51) BTKSYKTP53MAPTHTT
SCHEMBL4084987 0.89 BTK (0.50) BTKSYKTP53MAPTNPSR1
SCHEMBL4090528 0.88 BTK (0.65) BTKSYKNPC1RAB9AMEN1
SCHEMBL4090445 0.87 BTK (0.54) BTKSYKTP53MAPTLMNA
SCHEMBL4091766 0.87 BTK (0.58) BTKSYK
SCHEMBL4081255 0.85 BTK (0.55) BTKSYK
SCHEMBL4095557 0.84 BTK (0.55) BTKSYK
SCHEMBL13821203 0.84 BTK (0.55) BTKSYK
SCHEMBL4095483 0.80 BTK (0.65) BTKNPC1RAB9AMEN1KMT2A
SCHEMBL4090599 0.80 SYK (0.44) BTKSYKTDP1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 — — US claimed
US-8426441-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-04-23 — — US disclosed
US-8426441-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-04-23 — — US disclosed
US-8426441-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-04-23 — — US disclosed
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 — — US disclosed
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 — — US disclosed
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 — — US disclosed
WO-2009077334-A1 NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase BTK, SYK, LYN BTK 1/4885SYK 2/4885KDR 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.